JP5318867B2 - ピリドンｇｐｒ１１９ｇタンパク質共役受容体アゴニスト - Google Patents
ピリドンｇｐｒ１１９ｇタンパク質共役受容体アゴニスト Download PDFInfo
- Publication number
- JP5318867B2 JP5318867B2 JP2010517122A JP2010517122A JP5318867B2 JP 5318867 B2 JP5318867 B2 JP 5318867B2 JP 2010517122 A JP2010517122 A JP 2010517122A JP 2010517122 A JP2010517122 A JP 2010517122A JP 5318867 B2 JP5318867 B2 JP 5318867B2
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- cycloalkyl
- heterocyclyl
- alkyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- REXZYDCQIIOEKH-UHFFFAOYSA-N CC(C(OC(CC1)CCN1c1ncc(C2CC2)cn1)=C1)=CN(c(cc2)ccc2S(C)(=O)=O)C1=O Chemical compound CC(C(OC(CC1)CCN1c1ncc(C2CC2)cn1)=C1)=CN(c(cc2)ccc2S(C)(=O)=O)C1=O REXZYDCQIIOEKH-UHFFFAOYSA-N 0.000 description 1
- KIHYMXVCAPWCGE-UHFFFAOYSA-N CC(C)(C)CC(N(CC1)CCC1OC(C=CN1c(cc2)ccc2S(C)(=O)=O)=CC1=O)=O Chemical compound CC(C)(C)CC(N(CC1)CCC1OC(C=CN1c(cc2)ccc2S(C)(=O)=O)=CC1=O)=O KIHYMXVCAPWCGE-UHFFFAOYSA-N 0.000 description 1
- DYTGIMMOPCQYNV-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1OC(C=CN1c(cc2)ccc2S(C)(=O)=O)=CC1=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1OC(C=CN1c(cc2)ccc2S(C)(=O)=O)=CC1=O)=O DYTGIMMOPCQYNV-UHFFFAOYSA-N 0.000 description 1
- QVAJBALJKJIWLO-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1SC(C=CN1c(cc2)ccc2S(C)(=O)=O)=CC1=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1SC(C=CN1c(cc2)ccc2S(C)(=O)=O)=CC1=O)=O QVAJBALJKJIWLO-UHFFFAOYSA-N 0.000 description 1
- CRHGTVILFAKJSL-UHFFFAOYSA-N CC(C)(C)OC(N1CCC(COC(C=CN2c(cc3)ccc3S(C)(=O)=O)=CC2=O)CC1)=O Chemical compound CC(C)(C)OC(N1CCC(COC(C=CN2c(cc3)ccc3S(C)(=O)=O)=CC2=O)CC1)=O CRHGTVILFAKJSL-UHFFFAOYSA-N 0.000 description 1
- IFZIMMKTGQDMIR-UHFFFAOYSA-N CC(C)=Cc(cc1)ccc1OC(N(CC1)CCC1OC(C=CN1c(cc2)ccc2S(C)(=O)=O)=CC1=O)=O Chemical compound CC(C)=Cc(cc1)ccc1OC(N(CC1)CCC1OC(C=CN1c(cc2)ccc2S(C)(=O)=O)=CC1=O)=O IFZIMMKTGQDMIR-UHFFFAOYSA-N 0.000 description 1
- JPRJPZSSAFSKGO-UHFFFAOYSA-N CC(C)OC(N(CC1)CCC1OC(CCN1c2ccc(C(F)(F)F)cc2)=CC1=O)=O Chemical compound CC(C)OC(N(CC1)CCC1OC(CCN1c2ccc(C(F)(F)F)cc2)=CC1=O)=O JPRJPZSSAFSKGO-UHFFFAOYSA-N 0.000 description 1
- RKBOMBMZLXPISE-MAEOIBBWSA-N CC(C)c1n[o]c([C@H](CC2)CC[C@H]2OC(C=CN2c(cc3)ccc3S(C)(=O)=O)=CC2=O)n1 Chemical compound CC(C)c1n[o]c([C@H](CC2)CC[C@H]2OC(C=CN2c(cc3)ccc3S(C)(=O)=O)=CC2=O)n1 RKBOMBMZLXPISE-MAEOIBBWSA-N 0.000 description 1
- QQBDTURYXMYBHP-UHFFFAOYSA-N CCC(C)c1cnc(N(CC2)CCC2OC(C=CN2c(cc3)ccc3S(C)(=O)=O)=CC2=O)nc1 Chemical compound CCC(C)c1cnc(N(CC2)CCC2OC(C=CN2c(cc3)ccc3S(C)(=O)=O)=CC2=O)nc1 QQBDTURYXMYBHP-UHFFFAOYSA-N 0.000 description 1
- WZIFUGUUMWRJCX-UHFFFAOYSA-N CCCS(N(CC1)CCC1OC(C=CN1c(cc2)ccc2S(C)(=O)=O)=CC1=O)(=O)=O Chemical compound CCCS(N(CC1)CCC1OC(C=CN1c(cc2)ccc2S(C)(=O)=O)=CC1=O)(=O)=O WZIFUGUUMWRJCX-UHFFFAOYSA-N 0.000 description 1
- NPFWHLAYHMAART-UHFFFAOYSA-N CCCc1cnc(N(CC2)CCC2OC(C=CN2c(cc(c(C#N)c3)F)c3F)=CC2=O)nc1 Chemical compound CCCc1cnc(N(CC2)CCC2OC(C=CN2c(cc(c(C#N)c3)F)c3F)=CC2=O)nc1 NPFWHLAYHMAART-UHFFFAOYSA-N 0.000 description 1
- GUCFHVYTXJWYLE-UHFFFAOYSA-N CCCc1cnc(N(CC2)CCC2OC(C=CN2c(cc3)cc(F)c3F)=CC2=O)nc1 Chemical compound CCCc1cnc(N(CC2)CCC2OC(C=CN2c(cc3)cc(F)c3F)=CC2=O)nc1 GUCFHVYTXJWYLE-UHFFFAOYSA-N 0.000 description 1
- SEVHNZSDIOWQLR-UHFFFAOYSA-N CCCc1cnc(N(CC2)CCC2OC(C=CN2c(cc3)cc(F)c3NC(C(C)(C)C)=O)=CC2=O)nc1 Chemical compound CCCc1cnc(N(CC2)CCC2OC(C=CN2c(cc3)cc(F)c3NC(C(C)(C)C)=O)=CC2=O)nc1 SEVHNZSDIOWQLR-UHFFFAOYSA-N 0.000 description 1
- SVTNZVDHYHHOBA-UHFFFAOYSA-N CCCc1cnc(N(CC2)CCC2OC(C=CN2c(cc3)ccc3N(C)C(C(C)(C)C)=O)=CC2=O)nc1 Chemical compound CCCc1cnc(N(CC2)CCC2OC(C=CN2c(cc3)ccc3N(C)C(C(C)(C)C)=O)=CC2=O)nc1 SVTNZVDHYHHOBA-UHFFFAOYSA-N 0.000 description 1
- OQVWQEAKEQERTM-UHFFFAOYSA-N CCCc1cnc(N(CC2)CCC2OC(C=CN2c(cc3)cnc3S(C)(=O)=O)=CC2=O)nc1 Chemical compound CCCc1cnc(N(CC2)CCC2OC(C=CN2c(cc3)cnc3S(C)(=O)=O)=CC2=O)nc1 OQVWQEAKEQERTM-UHFFFAOYSA-N 0.000 description 1
- PZCHVNIDIIQDOF-UHFFFAOYSA-N CCOc1ncc(N(CC2)CCC2OC(C=CN2c(cc3)ccc3S(C)(=O)=O)=CC2=O)nc1 Chemical compound CCOc1ncc(N(CC2)CCC2OC(C=CN2c(cc3)ccc3S(C)(=O)=O)=CC2=O)nc1 PZCHVNIDIIQDOF-UHFFFAOYSA-N 0.000 description 1
- VTMPXNDYXFBTAC-UHFFFAOYSA-N COCCOC(N(CC1)CCC1OC(C=CN1c(cc2)ccc2S(C)(=O)=O)=CC1=O)=O Chemical compound COCCOC(N(CC1)CCC1OC(C=CN1c(cc2)ccc2S(C)(=O)=O)=CC1=O)=O VTMPXNDYXFBTAC-UHFFFAOYSA-N 0.000 description 1
- GNFFVQWMQYOFBV-UHFFFAOYSA-N CS(c(cc1)cc(Cl)c1N(C=CC(OC(CC1)CCN1c1ncc(C2CC2)cn1)=C1)C1=O)(=O)=O Chemical compound CS(c(cc1)cc(Cl)c1N(C=CC(OC(CC1)CCN1c1ncc(C2CC2)cn1)=C1)C1=O)(=O)=O GNFFVQWMQYOFBV-UHFFFAOYSA-N 0.000 description 1
- PBQNQKCHKSIVOQ-UHFFFAOYSA-N CS(c(cc1)ccc1N(C=CC(OC(CC1)CCN1C(Oc1cc(C(F)(F)F)ccc1)=O)=C1)C1=O)(=O)=O Chemical compound CS(c(cc1)ccc1N(C=CC(OC(CC1)CCN1C(Oc1cc(C(F)(F)F)ccc1)=O)=C1)C1=O)(=O)=O PBQNQKCHKSIVOQ-UHFFFAOYSA-N 0.000 description 1
- UOVFCGUGSZXOKQ-UHFFFAOYSA-N CS(c(cc1)ccc1N(C=CC(OC(CC1)CCN1c(cc1)ncc1-c1ccccc1)=C1)C1=O)(=O)=O Chemical compound CS(c(cc1)ccc1N(C=CC(OC(CC1)CCN1c(cc1)ncc1-c1ccccc1)=C1)C1=O)(=O)=O UOVFCGUGSZXOKQ-UHFFFAOYSA-N 0.000 description 1
- YQGXZXAOQTXIHS-UHFFFAOYSA-N CS(c(cc1)ccc1N(C=CC(OC(CC1)CCN1c(nc1)ncc1C1=CCCCC1)=C1)C1=O)(=O)=O Chemical compound CS(c(cc1)ccc1N(C=CC(OC(CC1)CCN1c(nc1)ncc1C1=CCCCC1)=C1)C1=O)(=O)=O YQGXZXAOQTXIHS-UHFFFAOYSA-N 0.000 description 1
- JHORQHNGCXPGNE-UHFFFAOYSA-N CS(c(cc1)ccc1N(C=CC(OC(CC1)CCN1c1ncc(C2CC2)cn1)=C1)C1=O)(=O)=O Chemical compound CS(c(cc1)ccc1N(C=CC(OC(CC1)CCN1c1ncc(C2CC2)cn1)=C1)C1=O)(=O)=O JHORQHNGCXPGNE-UHFFFAOYSA-N 0.000 description 1
- JVPHUEZESMNDFF-MDRHQERFSA-N C[C@H](C[C@@H]1C[C@@H](C2)OC(C=CN3c(cc4)ccc4S(C)(=O)=O)=CC3=O)[C@H]2N1C(OC(C)(CF)CF)=O Chemical compound C[C@H](C[C@@H]1C[C@@H](C2)OC(C=CN3c(cc4)ccc4S(C)(=O)=O)=CC3=O)[C@H]2N1C(OC(C)(CF)CF)=O JVPHUEZESMNDFF-MDRHQERFSA-N 0.000 description 1
- ZWWTWPUMGZRDKL-UHFFFAOYSA-N N#Cc(c(F)c1)ccc1N(C=C(C(OC(CC1)CCN1c1ncc(CCC(F)(F)F)cn1)=C1)Cl)C1=O Chemical compound N#Cc(c(F)c1)ccc1N(C=C(C(OC(CC1)CCN1c1ncc(CCC(F)(F)F)cn1)=C1)Cl)C1=O ZWWTWPUMGZRDKL-UHFFFAOYSA-N 0.000 description 1
- GXJSOTGAGRWBEN-UHFFFAOYSA-N N#Cc(c(F)c1)ccc1N(C=CC(OC(CC1)CCN1c1ncc(C2CC2)cn1)=C1)C1=O Chemical compound N#Cc(c(F)c1)ccc1N(C=CC(OC(CC1)CCN1c1ncc(C2CC2)cn1)=C1)C1=O GXJSOTGAGRWBEN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95016207P | 2007-07-17 | 2007-07-17 | |
| US60/950,162 | 2007-07-17 | ||
| PCT/US2008/070101 WO2009012275A1 (en) | 2007-07-17 | 2008-07-16 | Pyridone gpr119 g protein-coupled receptor agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013144778A Division JP2013237680A (ja) | 2007-07-17 | 2013-07-10 | ピリドンｇｐｒ１１９ｇタンパク質共役受容体アゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010533726A JP2010533726A (ja) | 2010-10-28 |
| JP2010533726A5 JP2010533726A5 (OSRAM) | 2011-02-24 |
| JP5318867B2 true JP5318867B2 (ja) | 2013-10-16 |
Family
ID=39864683
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517122A Expired - Fee Related JP5318867B2 (ja) | 2007-07-17 | 2008-07-16 | ピリドンｇｐｒ１１９ｇタンパク質共役受容体アゴニスト |
| JP2010517123A Expired - Fee Related JP5301539B2 (ja) | 2007-07-17 | 2008-07-16 | Ｇｐｒ１１９ｇタンパク質共役受容体の調節方法および選択された化合物 |
| JP2013144778A Withdrawn JP2013237680A (ja) | 2007-07-17 | 2013-07-10 | ピリドンｇｐｒ１１９ｇタンパク質共役受容体アゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517123A Expired - Fee Related JP5301539B2 (ja) | 2007-07-17 | 2008-07-16 | Ｇｐｒ１１９ｇタンパク質共役受容体の調節方法および選択された化合物 |
| JP2013144778A Withdrawn JP2013237680A (ja) | 2007-07-17 | 2013-07-10 | ピリドンｇｐｒ１１９ｇタンパク質共役受容体アゴニスト |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US8003796B2 (OSRAM) |
| EP (2) | EP2173737B1 (OSRAM) |
| JP (3) | JP5318867B2 (OSRAM) |
| KR (2) | KR20100045471A (OSRAM) |
| CN (3) | CN101801957A (OSRAM) |
| AR (2) | AR067569A1 (OSRAM) |
| AT (2) | ATE524460T1 (OSRAM) |
| AU (2) | AU2008276055B2 (OSRAM) |
| BR (2) | BRPI0815097A2 (OSRAM) |
| CA (2) | CA2693444A1 (OSRAM) |
| CL (2) | CL2008002111A1 (OSRAM) |
| CO (1) | CO6160315A2 (OSRAM) |
| CY (2) | CY1112151T1 (OSRAM) |
| DK (2) | DK2173737T3 (OSRAM) |
| EA (2) | EA016595B1 (OSRAM) |
| ES (2) | ES2378914T3 (OSRAM) |
| HR (2) | HRP20110806T1 (OSRAM) |
| IL (1) | IL228120A0 (OSRAM) |
| NZ (2) | NZ582664A (OSRAM) |
| PE (2) | PE20090449A1 (OSRAM) |
| PL (2) | PL2170864T3 (OSRAM) |
| PT (2) | PT2173737E (OSRAM) |
| SI (2) | SI2173737T1 (OSRAM) |
| TW (2) | TW200904439A (OSRAM) |
| WO (2) | WO2009012275A1 (OSRAM) |
| ZA (2) | ZA201000151B (OSRAM) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006059778A1 (ja) * | 2004-12-01 | 2006-06-08 | Banyu Pharmaceutical Co., Ltd. | 置換ピリドン誘導体 |
| EP2144902B1 (en) | 2007-05-04 | 2012-05-16 | Bristol-Myers Squibb Company | [6,6]and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
| CA2693444A1 (en) | 2007-07-17 | 2009-01-22 | Bristol-Myers Squibb Company | Method for modulating gpr119 g protein-coupled receptor and selected compounds |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| MX2010012848A (es) | 2008-06-03 | 2011-03-01 | Intermune Inc | Compuestos y metodos para tratar trastornos inflamatorios y fibroticos. |
| JP2011528365A (ja) | 2008-07-16 | 2011-11-17 | シェーリング コーポレイション | Ｇｐｒ１１９モジュレーターとしての二環式ヘテロ環誘導体およびそれらの使用方法 |
| TW201006821A (en) * | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| US8815876B2 (en) | 2008-07-16 | 2014-08-26 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and methods of use thereof |
| GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| JP2012520868A (ja) * | 2009-03-20 | 2012-09-10 | ファイザー・インク | ３−オキサ−７−アザビシクロ［３．３．１］ノナン |
| AR077215A1 (es) | 2009-06-24 | 2011-08-10 | Boehringer Ingelheim Int | Derivados de piperidina, composiciones farmaceuticas y metodos relacionados con ellos |
| US8481731B2 (en) | 2009-06-24 | 2013-07-09 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| US8415367B2 (en) * | 2010-04-08 | 2013-04-09 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators |
| WO2011140161A1 (en) | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
| BR112012028445A2 (pt) | 2010-05-06 | 2016-07-19 | Bristol Myers Squibb Co | compostos de heteroarila bicíclica como moduladores de gpr119 |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| EP2625177B1 (en) | 2010-10-08 | 2015-07-29 | Cadila Healthcare Limited | Novel gpr 119 agonists |
| US9359300B2 (en) | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
| HRP20181788T1 (hr) | 2010-12-06 | 2018-12-28 | Aclaris Therapeutics, Inc. | Supstituirani spojevi piridinon-piridinil |
| WO2012123449A1 (en) * | 2011-03-14 | 2012-09-20 | Boehringer Ingelheim International Gmbh | N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators |
| EP2718279B1 (en) | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Novel compounds as modulators of gpr-119 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2850073B1 (en) | 2012-05-16 | 2017-07-19 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators |
| CA2878625A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| MX361479B (es) * | 2012-11-13 | 2018-12-06 | Nissan Chemical Ind Ltd Star | Compuesto de 2-piridona. |
| CN102993088A (zh) * | 2012-12-31 | 2013-03-27 | 东华大学 | 一种4-羟基-2-吡啶酮的制备方法 |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
| TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途 |
| TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
| HUE054178T2 (hu) | 2013-06-07 | 2021-08-30 | Aclaris Therapeutics Inc | Metil/fluor-piridinil-metoxi-szubsztituált piridinon-piridinil-vegyületek és fluor-pirimidinil-metoxi-szubsztituált piridinon-piridinil-vegyületek |
| EP3010893B1 (de) | 2013-06-20 | 2019-10-02 | Bayer CropScience Aktiengesellschaft | Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide |
| EP3010889B1 (de) | 2013-06-20 | 2018-10-03 | Bayer CropScience Aktiengesellschaft | Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide |
| ES2728531T3 (es) | 2013-07-08 | 2019-10-25 | Bayer Cropscience Ag | Derivados de arilsulfuro y arilsulfóxido de seis miembros enlazados con C-N como agentes para combatir parásitos |
| CN106459042B (zh) | 2014-04-02 | 2019-06-28 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
| EP2929883A1 (en) | 2014-04-08 | 2015-10-14 | Institut Pasteur | Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors |
| KR102455043B1 (ko) | 2014-09-11 | 2022-10-13 | 얀센 파마슈티카 엔.브이. | 치환된 2-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도 |
| WO2016130652A1 (en) | 2015-02-10 | 2016-08-18 | Vanderbilt University | Negative allosteric modulators of metabotropic glutamate receptor 3 |
| JP6578116B2 (ja) * | 2015-03-25 | 2019-09-18 | 公益財団法人相模中央化学研究所 | 一置換（フルオロアルキル）エチレン類及びその製造方法 |
| US10865194B2 (en) | 2017-11-03 | 2020-12-15 | Fondazione Istituto Italiano Di Tecnologia | Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions |
| AU2021228729A1 (en) | 2020-02-28 | 2022-09-22 | Kallyope, Inc. | GPR40 agonists |
| WO2021195475A1 (en) | 2020-03-27 | 2021-09-30 | Aclaris Therapeutics, Inc. | Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds |
| UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
| WO2022081573A1 (en) * | 2020-10-12 | 2022-04-21 | University Of Tennessee Research Foundation | Transient receptor potential canonical 3 inhibitors and methods of use thereof |
| CN115504927A (zh) * | 2022-08-15 | 2022-12-23 | 广西中医药大学 | 4-甲基-2-对甲苯基-6-羰基吡啶-3-甲酸及其制备方法和用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3826643A (en) | 1967-08-07 | 1974-07-30 | American Cyanamid Co | Method of controlling undesirable plant species using 3-nitropyridines |
| US5776983A (en) * | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US5488064A (en) * | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
| US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
| US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US6566384B1 (en) * | 1996-08-07 | 2003-05-20 | Darwin Discovery Ltd. | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
| TR200100149T2 (tr) | 1998-07-06 | 2001-10-22 | Bristol-Myers Squibb Company | Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler |
| EP1140862A4 (en) | 1998-12-23 | 2004-07-28 | Bristol Myers Squibb Pharma Co | THROMBIN OR Xa FACTOR INHIBITORS |
| CA2413241A1 (en) | 2000-06-29 | 2002-01-10 | Bristol-Myers Squibb Pharma Company | Thrombin or factor xa inhibitors |
| DE60125227T2 (de) | 2000-12-01 | 2007-09-20 | Astellas Pharma Inc. | Verfahren zum screening von diabetes-heilverfahren |
| US7482366B2 (en) * | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| CA2469435A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
| EP1490064B1 (en) * | 2002-02-14 | 2009-11-18 | Pharmacia Corporation | Substituted pyridinones as modulators of p38 map kinase |
| AU2004205642C1 (en) | 2003-01-14 | 2012-01-12 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| KR20050106033A (ko) | 2003-02-24 | 2005-11-08 | 아레나 파마슈티칼스, 인크. | 글루코스 대사 조절제로서의 페닐- 및피리딜피페리딘-유도체 |
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| US7003597B2 (en) * | 2003-07-09 | 2006-02-21 | International Business Machines Corporation | Dynamic reallocation of data stored in buffers based on packet size |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| UA86943C2 (ru) * | 2003-07-11 | 2009-06-10 | Арена Фармасьютикалз, Инк. | Тризамещенные производные арилов и гетероарилов как модуляторы метаболизма и профилактика и лечение связанных с ними нарушений |
| BRPI0412689A (pt) * | 2003-07-14 | 2006-10-03 | Arena Pharm Inc | derivados de heteroarila e arila fundida como moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a ele |
| US20070088163A1 (en) | 2003-09-12 | 2007-04-19 | Kemia, Inc. | Modulators of calcitonin and amylin activity |
| CA2558272C (en) * | 2004-03-05 | 2011-02-15 | Banyu Pharmaceutical Co., Ltd. | Pyridone derivative |
| US20080269114A1 (en) | 2004-03-17 | 2008-10-30 | 7Tm Pharma A/S | Y4 Selective Receptor Agonists For Thereapeutic Interventions |
| MXPA06012683A (es) | 2004-05-03 | 2007-01-16 | Hoffmann La Roche | Derivados de indolilo como moduladores de receptor x del higado. |
| WO2005121121A2 (en) | 2004-06-04 | 2005-12-22 | Arena Pharmaceuticals, Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| WO2006067532A1 (en) | 2004-12-24 | 2006-06-29 | Prosidion Ltd | G-protein coupled receptor agonists |
| MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| JP5349960B2 (ja) * | 2005-06-23 | 2013-11-20 | エモリー ユニバーシティー | 腫瘍画像化のためのアミノ酸類似体の立体選択的合成 |
| US20090325924A1 (en) * | 2005-06-30 | 2009-12-31 | Stuart Edward | GPCR Agonists |
| WO2007003961A2 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| JP2010526146A (ja) * | 2007-05-04 | 2010-07-29 | ブリストル−マイヤーズ スクイブ カンパニー | ［６，５］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト |
| EP2144902B1 (en) * | 2007-05-04 | 2012-05-16 | Bristol-Myers Squibb Company | [6,6]and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
| CA2693444A1 (en) * | 2007-07-17 | 2009-01-22 | Bristol-Myers Squibb Company | Method for modulating gpr119 g protein-coupled receptor and selected compounds |
-
2008
- 2008-07-16 CA CA2693444A patent/CA2693444A1/en not_active Abandoned
- 2008-07-16 PT PT08781868T patent/PT2173737E/pt unknown
- 2008-07-16 DK DK08781868.8T patent/DK2173737T3/da active
- 2008-07-16 JP JP2010517122A patent/JP5318867B2/ja not_active Expired - Fee Related
- 2008-07-16 AU AU2008276055A patent/AU2008276055B2/en not_active Ceased
- 2008-07-16 KR KR1020107003332A patent/KR20100045471A/ko not_active Withdrawn
- 2008-07-16 CN CN200880108168A patent/CN101801957A/zh active Pending
- 2008-07-16 CA CA2693439A patent/CA2693439A1/en not_active Abandoned
- 2008-07-16 CN CN2008801081672A patent/CN101801956B/zh not_active Expired - Fee Related
- 2008-07-16 DK DK08781867.0T patent/DK2170864T3/da active
- 2008-07-16 BR BRPI0815097A patent/BRPI0815097A2/pt not_active IP Right Cessation
- 2008-07-16 HR HR20110806T patent/HRP20110806T1/hr unknown
- 2008-07-16 TW TW097127045A patent/TW200904439A/zh unknown
- 2008-07-16 ES ES08781868T patent/ES2378914T3/es active Active
- 2008-07-16 SI SI200830592T patent/SI2173737T1/sl unknown
- 2008-07-16 PE PE2008001197A patent/PE20090449A1/es not_active Application Discontinuation
- 2008-07-16 EP EP08781868A patent/EP2173737B1/en not_active Not-in-force
- 2008-07-16 EP EP08781867A patent/EP2170864B1/en not_active Not-in-force
- 2008-07-16 AT AT08781867T patent/ATE524460T1/de active
- 2008-07-16 EA EA201000211A patent/EA016595B1/ru not_active IP Right Cessation
- 2008-07-16 WO PCT/US2008/070101 patent/WO2009012275A1/en not_active Ceased
- 2008-07-16 US US12/173,856 patent/US8003796B2/en active Active
- 2008-07-16 PE PE2008001196A patent/PE20090888A1/es not_active Application Discontinuation
- 2008-07-16 SI SI200830464T patent/SI2170864T1/sl unknown
- 2008-07-16 PL PL08781867T patent/PL2170864T3/pl unknown
- 2008-07-16 BR BRPI0814428-1A2A patent/BRPI0814428A2/pt not_active IP Right Cessation
- 2008-07-16 EA EA201000210A patent/EA018709B1/ru not_active IP Right Cessation
- 2008-07-16 AT AT08781868T patent/ATE540945T1/de active
- 2008-07-16 KR KR1020107003333A patent/KR20100051814A/ko not_active Withdrawn
- 2008-07-16 TW TW097127046A patent/TW200904440A/zh unknown
- 2008-07-16 ES ES08781867T patent/ES2371515T3/es active Active
- 2008-07-16 AR ARP080103061A patent/AR067569A1/es not_active Application Discontinuation
- 2008-07-16 AU AU2008276057A patent/AU2008276057B2/en not_active Ceased
- 2008-07-16 AR ARP080103060A patent/AR067568A1/es unknown
- 2008-07-16 US US12/173,864 patent/US7928230B2/en active Active
- 2008-07-16 JP JP2010517123A patent/JP5301539B2/ja not_active Expired - Fee Related
- 2008-07-16 NZ NZ582664A patent/NZ582664A/en not_active IP Right Cessation
- 2008-07-16 WO PCT/US2008/070103 patent/WO2009012277A1/en not_active Ceased
- 2008-07-16 NZ NZ582661A patent/NZ582661A/en not_active IP Right Cessation
- 2008-07-16 CN CN201310495045.6A patent/CN103550218A/zh active Pending
- 2008-07-16 PT PT08781867T patent/PT2170864E/pt unknown
- 2008-07-16 PL PL08781868T patent/PL2173737T3/pl unknown
- 2008-07-16 HR HR20120221T patent/HRP20120221T1/hr unknown
- 2008-07-17 CL CL200802111A patent/CL2008002111A1/es unknown
- 2008-07-17 CL CL200802110A patent/CL2008002110A1/es unknown
-
2010
- 2010-01-08 ZA ZA2010/00151A patent/ZA201000151B/en unknown
- 2010-01-15 ZA ZA2010/00326A patent/ZA201000326B/en unknown
- 2010-01-15 CO CO10003756A patent/CO6160315A2/es unknown
-
2011
- 2011-03-07 US US13/041,564 patent/US8178561B2/en active Active
- 2011-06-14 US US13/159,497 patent/US8232404B2/en active Active
- 2011-12-14 CY CY20111101241T patent/CY1112151T1/el unknown
-
2012
- 2012-04-09 CY CY20121100343T patent/CY1112751T1/el unknown
- 2012-04-24 US US13/454,789 patent/US20120232048A1/en not_active Abandoned
- 2012-06-12 US US13/494,489 patent/US8513424B2/en active Active
-
2013
- 2013-07-10 JP JP2013144778A patent/JP2013237680A/ja not_active Withdrawn
- 2013-08-26 IL IL228120A patent/IL228120A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5318867B2 (ja) | ピリドンｇｐｒ１１９ｇタンパク質共役受容体アゴニスト | |
| US8372837B2 (en) | Pyridone and pyridazone analogues as GPR119 modulators | |
| ES2388967T3 (es) | Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G | |
| US8940716B2 (en) | Bicyclic heteroaryl compounds as GPR119 modulators | |
| JP2010526146A (ja) | ［６，５］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト | |
| HK1143136B (en) | Pyridone gpr119 g protein-coupled receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110106 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130219 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130517 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130611 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130710 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |